Seres Therapeutics Inc

NASDAQ: MCRB
$1.13
+$0.08 (+7.6%)
Closing Price on September 20, 2024

MCRB Chart and Intraday Price

MCRB Company Data

Asset Type Stock
Exchange NASDAQ
Currency USD
Country USA
Sector LIFE SCIENCES
Industry PHARMACEUTICAL PREPARATIONS
Address 200 SIDNEY STREET, CAMBRIDGE, MA, US
Fiscal Year End December
Latest Quarter 9/30/2023
Market Cap 158.99M USD
Shares Outstanding 129,257,000
Seres Therapeutics Inc is at the forefront of developing microbiome therapeutics, focusing on restoring health by modulating the microbiome. Their leading product, SER-109, aims to treat recurrent Clostridioides difficile infection and has completed Phase III clinical trials. The company's pipeline also includes treatments for gastrointestinal infections and ulcerative colitis, among others. Through strategic partnerships, Seres Therapeutics is advancing research in microbiome technology for various diseases, including cancer. Founded in 2010 and based in Cambridge, Massachusetts, the company is pioneering in leveraging the microbiome for therapeutic purposes.

MCRB Articles

2015 was one of the worst years for IPOs in the past decade. Only 2016 and 2022 were worse. But there were some big winners.
One of Cathie Wood's ARK Invest exchange-traded funds sold over 840,000 shares of Seres Therapeutics on August 30.
Friday's top analyst upgrades and downgrades included American Airlines, Boston Beer, CarMax, Danaher, Domino’s Pizza, D.R. Horton, Monster Beverage and Starbucks.
Tuesday's top analyst upgrades and downgrades included Bed Bath & Beyond, Booking, Carvana, Electronic Arts, EOG Resources, Honeywell, Intercontinental Exchange, Livongo Health, Nucor, Seres...